503 results on '"Subramony, S."'
Search Results
2. Propensity matched comparison of omaveloxolone treatment to Friedreich ataxia natural history data.
3. Frataxin analysis using triple quadrupole mass spectrometry: application to a large heterogeneous clinical cohort
4. A Milestone in the Treatment of Ataxias: Approval of Omaveloxolone for Friedreich Ataxia
5. Clinically Meaningful Magnetic Resonance Endpoints Sensitive to Preataxic Spinocerebellar Ataxia Types 1 and 3.
6. Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): a randomised, double-blind, placebo-controlled phase 2b trial
7. A non-synonymous single nucleotide polymorphism in SIRT6 predicts neurological severity in Friedreich ataxia.
8. Scale for Ocular Motor Disorders in Ataxia (SODA): Procedures and Basic Understanding
9. Body Mass Index and Height in the Friedreich Ataxia Clinical Outcome Measures Study.
10. Safety and Efficacy of Omaveloxolone in Friedreich Ataxia (MOXIe Study).
11. Dysphagia in spinocerebellar ataxias type 1, 2, 3 and 6.
12. The impact of ethnicity on the clinical presentations of spinocerebellar ataxia type 3.
13. Increased Risk of Suicidal Ideation in Patients with Spinocerebellar Ataxias (S2.009)
14. The MOXIe Trial of Omaveloxolone in Friedreich Ataxia: Exploring the Transient Nature of Treatment-emergent Adverse Events (P7-3.016)
15. Tremor in the Degenerative Cerebellum: Towards the Understanding of Brain Circuitry for Tremor.
16. Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia.
17. Comprehensive systematic review summary: Treatment of cerebellar motor dysfunction and ataxia: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
18. The Initial Symptom and Motor Progression in Spinocerebellar Ataxias.
19. Postural Tremor and Ataxia Progression in Spinocerebellar Ataxias.
20. Friedreich Ataxia Caregiver-Reported Health Index.
21. Depression and clinical progression in spinocerebellar ataxias.
22. Frataxin analysis using triple quadrupole mass spectrometry: application to a large heterogeneous clinical cohort
23. O18 Topline safety and efficacy data analysis of phase 1/2 clinical trial evaluating AOC 1001 in adults with myotonic dystrophy type 1: MARINA TM
24. P132 Quantifying skeletal muscle fat fraction and function using whole body magnetic resonance imaging (MRI) in men with Becker muscular dystrophy
25. VP55 Topline data analysis of the phase 1/2 clinical trial evaluating AOC 1001 in adult patients with myotonic dystrophy type 1: MARINA
26. Clinical characteristics of patients with spinocerebellar ataxias 1, 2, 3 and 6 in the US; A prospective observational study
27. Mutation in the Kv3.3 Voltage-Gated Potassium Channel Causing Spinocerebellar Ataxia 13 Disrupts Sound-Localization Mechanisms
28. C-terminal proline deletions in KCNC3 cause delayed channel inactivation and an adult-onset progressive SCA13 with spasticity
29. A Milestone in the Treatment of Ataxias: Approval of Omaveloxolone for Friedreich Ataxia
30. Motor Outcomes to Validate Evaluations in Facioscapulohumeral muscular dystrophy (MOVE FSHD): Preliminary Baseline Characteristics (S7.004)
31. Fragile X-associated tremor ataxia syndrome with co-occurrent progressive supranuclear palsy-like neuropathology
32. Epidemiology of Peripheral Neuropathies
33. P.210 A phase 1/2 clinical trial evaluating the safety and pharmacokinetics of AOC 1001 in adults with myotonic dystrophy type 1: MARINA study design
34. SPG7 and Impaired Emotional Communication
35. Sensory and corticospinal signs before ataxia onset in SCA1 and SCA3: the READISCA study
36. Ataxias
37. A non-synonymous single nucleotide polymorphism in SIRT6 predicts neurological severity in Friedreich ataxia
38. C9orf72 repeat expansions as genetic modifiers for depression in spinocerebellar ataxias
39. RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia
40. A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 48-Week Study of the Efficacy and Safety of Losmapimod in Subjects with FSHD: ReDUX4 (S23.007)
41. Reachable Workspace to Evaluate Efficacy of Losmapimod in Subjects with FSHD in Two Phase 2 Studies (P4-13.008)
42. Whole Body MRI Quantitative muscle analysis to evaluate Efficacy of Losmapimod in a Phase 2 Placebo-Controlled Study in Subjects with FSHD (ReDUX4) (S23.009)
43. Generation of Human-Induced Pluripotent Stem Cells to Model Spinocerebellar Ataxia Type 2 In vitro
44. Correction to: SPG7 and Impaired Emotional Communication
45. Coenzyme Q10 and Spinocerebellar Ataxias
46. Apraxia in anti-glutamic acid decarboxylase–associated stiff person syndrome: Link to corticobasal degeneration?
47. Analysis of the visual system in Friedreich ataxia
48. Improving the efficacy of exome sequencing at a quaternary care referral centre: novel mutations, clinical presentations and diagnostic challenges in rare neurogenetic diseases
49. Steady or not following thalamic deep brain stimulation for essential tremor
50. Vascular burden and clinical progression in spinocerebellar ataxias: 1293
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.